RecruitingPHASE1, PHASE2NCT07012031

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Studying Mucolipidosis type II

Last synced from ClinicalTrials.gov May 13, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Andreas N Saltos
University Health Network Princess Margaret Cancer Center LAO
Intervention: Biopsy Procedure(procedure)
Enrollment: 37 target
Eligibility: 18 years · All sexes
Timeline: 2026 – 2027

Study locations (9)

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Moffitt Cancer Center-International Plaza, Tampa, Florida, United States
Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Moffitt Cancer Center at Wesley Chapel, Wesley Chapel, Florida, United States
Case Western Reserve University, Cleveland, Ohio, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
University of Virginia Cancer Center, Charlottesville, Virginia, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07012031 on ClinicalTrials.gov

Other trials for Mucolipidosis type II

Additional recruiting or active studies for the same condition.

See all trials for Mucolipidosis type II →

← Back to all trials